Several studies have examined the impact of sodium-glucose co-transporter 2 (SGLT2) inhibitors on the occurrence of non-alcoholic fatty liver disease (NAFLD) and/or NASH in rodent models and humans [5,6,7,8,9]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.